1. PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more
- Author
-
Yingying Lin, Shan Huang, Yuanjie Qi, Li Xie, Junying Jiang, Hua Li, and Zhiwei Chen
- Subjects
PSGL-1 ,cervical cancer ,prognosis ,tumor-infiltrating-immune cells ,immunotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundMacrophages secrete many cytokines and chemokines, which can provoke either an anti-tumor or pro-tumor immune response. P-selectin glycoprotein ligand-1 (PSGL-1) is expressed in macrophages and plays a vital role in synergizing for a more robust anti-tumor response. However, there are few studies about PSGL-1 expression status and clinical value of biological function in cervical cancer.MethodsIn this study, 565 participants were enrolled. PSGL-1 mRNA was detected by real-time quantitative PCR (qPCR) with cervical cytology specimens. The relationship between PSGL-1 and cervical intraepithelial neoplasia in two grades and more (CIN2+) was analyzed, and the optimal cut-off values of PSGL-1 to predict CIN2+ were calculated. In addition, the clinical significance of PSGL-1 in cervical cancer was determined by Kaplan-Meier Cox regression based on the database.ResultsThe mean PSGL-1 increased significantly with cervical lesion development, especially compared with CIN2+ (p
- Published
- 2023
- Full Text
- View/download PDF